Marinomed Biotech AG (the "Company") announces that the Company was informed by the three shareholders Acropora Beteiligungs GmbH ("Acropora"), VETWIDI Forschungsholding GmbH ("VETWIDI") and BVT Beteiligungsverwaltung und Treuhand GmbH ("BVT") on 22 January 2020 that Acropora, VETWIDI and BVT intend to sell in total up to 55,000Marinomed shares, ISIN ATMARINOMED6, plus an upsize alternative of up to further 50,000 Marinomed shares from their respective holdings through an accelerated bookbuilding transaction (the "Transaction").
Immediately after receiving the notification from Acropora, VETWIDI and BVT, the Company has applied for suspension from trading of all Marinomed shares, ISIN ATMARINOMED6, on the Official Market of the Vienna Stock Exchange. The suspension from trading of the Marinomed shares on the Official Market of the Vienna Stock Exchange is intended to last until the result of the Transaction is announced.
Acropora, VETWIDI and BVT intend to sell in total up to 55,000 Marinomed shares through the ABB. This corresponds to up to 3.7 per cent. of the share capital of the Company. Acropora, VETWIDI and BVT reserve the right to decide – in consultation with Erste Group Bank AG as sole bookrunner – on selling up to 50,000 additional Marinomed shares (corresponding to approximately 3.4 per cent. of the share capital of the Company) in the event of strong demand (upsize alternative).
